Abstract: The present invention relates to novel salts, particularly crystalline salts, of 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one (I) which are particularly suitable for use in the manufacture of pharmaceutical 5 compositions. Furthermore, the invention relates to pharmaceutical compositions comprising such novel salts. Compound (I) is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated cancers, such as prostate cancer and breast cancer.
| # | Name | Date |
|---|---|---|
| 1 | 202317058209-STATEMENT OF UNDERTAKING (FORM 3) [30-08-2023(online)].pdf | 2023-08-30 |
| 2 | 202317058209-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [30-08-2023(online)].pdf | 2023-08-30 |
| 3 | 202317058209-FORM 1 [30-08-2023(online)].pdf | 2023-08-30 |
| 4 | 202317058209-DRAWINGS [30-08-2023(online)].pdf | 2023-08-30 |
| 5 | 202317058209-DECLARATION OF INVENTORSHIP (FORM 5) [30-08-2023(online)].pdf | 2023-08-30 |
| 6 | 202317058209-COMPLETE SPECIFICATION [30-08-2023(online)].pdf | 2023-08-30 |
| 7 | 202317058209-Proof of Right [17-10-2023(online)].pdf | 2023-10-17 |
| 8 | 202317058209-FORM-26 [19-10-2023(online)].pdf | 2023-10-19 |
| 9 | 202317058209-FORM 3 [27-02-2024(online)].pdf | 2024-02-27 |
| 10 | 202317058209-FORM 18 [06-02-2025(online)].pdf | 2025-02-06 |